Study to Assess the Effect on Recovery of GI Motility and Safety and to Determine the Optimal Dose of LD02GIFRO

NCT01624571 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

147

Enrollment

INDUSTRY

Sponsor class

Conditions

Colon Resection
_large Interstinal Surgery

Interventions

DRUG: LD02GIFRO

Sponsor

LG Life Sciences